𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells

✍ Scribed by Lihong Peng; Jining Wang; Peter J. Malloy; David Feldman

Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
489 KB
Volume
122
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Insulin‐like growth factor binding protein‐3 (IGFBP‐3), an antiproliferative and proapoptotic protein, has been shown to be upregulated by growth inhibitory concentrations of androgens in LNCaP human prostate cancer (PCa) cells, but the mechanism of regulation and the role of IGFBP‐3 in the modulation of PCa cell proliferation are unknown. In this study, we have examined the effects of a range of concentrations of the synthetic androgen R1881 on IGFBP‐3 expression and cell growth in LNCaP cells. We have also investigated the role of androgen‐stimulated IGFBP‐3 in androgen‐induced growth inhibition. We show that low doses of R1881 stimulate LNCaP cell proliferation, but do not induce IGFBP‐3 expression, whereas high doses of R1881 that inhibit cell growth, significantly increase expression of IGFBP‐3. Importantly, we demonstrate that the combination of calcitriol and androgens not only synergistically upregulates IGFBP‐3 expression but also inhibits cell growth better than either hormone alone. siRNA knockdown of IGFBP‐3 expression partially reverses the growth inhibition by calcitriol and by androgens. Furthermore, we find that the growth inhibitory dose of R1881 leads to increases in the cyclin dependent kinase inhibitors (CDKIs), p21 and p27 as well as to G1 arrest. These changes can be blocked or partially reversed by IGFBP‐3 siRNA, indicating that the induction of CDKIs is downstream of IGFBP‐3. Our data suggest, for the first time, that IGFBP‐3 is involved in the antiproliferative action of high doses of androgens partly through p21 and p27 pathways and that IGFBP‐3 may contribute significantly to androgen‐induced changes in LNCaP cell growth. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Role of insulin-like growth factor bindi
Role of insulin-like growth factor binding protein-3 in breast cancer cell growth
✍ Lynette J. Schedlich; Lloyd D. Graham 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

The mitogenic effects of insulin-like growth factors (IGFs) are regulated by a family of insulin-like growth factor binding proteins (IGFBPs). One member of this family, IGFBP-3, mediates the growth-inhibitory and apoptosis-inducing effects of a number of growth factors and hormones such as transfor

Novel stimulatory role for insulin-like
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells
✍ Michael G. Moore; Lawrence A. Wetterau; Malik J. Francis; Donna M. Peehl; Pincha 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 235 KB 👁 1 views

## Abstract The insulin‐like growth factor (IGF) axis is a complex system composed of 2 mitogenic ligands, IGF‐I and ‐II, 2 receptors, IGF‐1R and IGF‐2R, and 6 binding proteins, IGFBP‐1 to ‐6. The IGFBPs exert their actions through their regulation of IGF bioavailability for IGF receptors. In addit

Serum insulin-like growth factor-I, insu
Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death
✍ Yingsong Lin; Akiko Tamakoshi; Shogo Kikuchi; Kiyoko Yagyu; Yuki Obata; Teruo Is 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 75 KB

## Abstract Recent epidemiological studies have shown that high serum levels of insulin‐like growth factor‐I (IGF‐I) are associated with an increased risk of lung, colon, breast and prostate cancer. Since very few studies have addressed the role of serum levels of IGF‐I in the development of pancre

Insulin-like growth factor binding prote
Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells
✍ C.A. Fowler; C.M. Perks; P.V. Newcomb; P.B. Savage; J.R. Farndon; J.M.P. Holly 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 145 KB 👁 2 views

Variability in response to chemotherapy is poorly understood. Paclitaxel-induced apoptosis was assessed in human Hs578T breast cancer cells, using the MTT assay, cell counting, morphological features and flow cytometry. Pre-dosing cells with non-glycosylated insulin-like growth factor binding protei